Literature DB >> 23001481

Regulation of hepatitis C virus replication and gene expression by the MAPK-ERK pathway.

Rongjuan Pei1, Xiaoyong Zhang, Song Xu, Zhongji Meng, Michael Roggendorf, Mengji Lu, Xinwen Chen.   

Abstract

The mitogen activated protein kinases-extracellular signal regulated kinases (MAPK-ERK) pathway is involved in regulation of multiple cellular processes including the cell cycle. In the present study using a Huh7 cell line Con1 with an HCV replicon, we have shown that the MAPK-ERK pathway plays a significant role in the modulation of HCV replication and protein expression and might influence IFN-α signalling. Epithelial growth factor (EGF) was able to stimulate ERK activation and decreased HCV RNA load while a MAPK-ERK pathway inhibitor U0126 led to an elevated HCV RNA load and higher NS5A protein amounts in Con1 cells. It could be further demonstrated that the inhibition of the MAPK-ERK pathway facilitated the translation directed by the HCV internal ribosome entry site. Consistently, a U0126 treatment enhanced activity of the HCV reporter replicon in transient transfection assays. Thus, the MAPK-ERK pathway plays an important role in the regulation of HCV gene expression and replication. In addition, cyclin-dependent kinases (CDKs) downstream of ERK may also be involved in the modulation of HCV replication since roscovitine, an inhibitor of CDKs had a similar effect to that of U0126. Modulation of the cell cycle progression by cell cycle inhibitor or RNAi resulted consistently in changes of HCV RNA levels. Further, the replication of HCV replicon in Con1 cells was inhibited by IFN-α. The inhibitory effect of IFN-α could be partly reversed by pre-incubation of Con-1 cells with inhibitors of the MAPK-ERK pathway and CDKs. It could be shown that the MAPK-ERK inhibitors are able to partially modulate the expression of interferon-stimulated genes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23001481      PMCID: PMC8218137          DOI: 10.1007/s12250-012-3257-6

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  41 in total

1.  Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling.

Authors:  Eileen Foy; Kui Li; Rhea Sumpter; Yueh-Ming Loo; Cynthia L Johnson; Chunfu Wang; Penny Mar Fish; Mitsutoshi Yoneyama; Takashi Fujita; Stanley M Lemon; Michael Gale
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

Review 2.  Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture.

Authors:  Ralf Bartenschlager
Journal:  Curr Opin Microbiol       Date:  2006-06-30       Impact factor: 7.934

3.  Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1.

Authors:  H Aktas; H Cai; G M Cooper
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

Review 4.  Mitogen-activated protein kinases in cell-cycle control.

Authors:  Rebecca A MacCorkle; Tse-Hua Tan
Journal:  Cell Biochem Biophys       Date:  2005       Impact factor: 2.194

5.  Perturbation of epidermal growth factor receptor complex formation and Ras signalling in cells harbouring the hepatitis C virus subgenomic replicon.

Authors:  Andrew Macdonald; Julia Ka Yu Chan; Mark Harris
Journal:  J Gen Virol       Date:  2005-04       Impact factor: 3.891

6.  Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I.

Authors:  Rhea Sumpter; Yueh-Ming Loo; Eileen Foy; Kui Li; Mitsutoshi Yoneyama; Takashi Fujita; Stanley M Lemon; Michael Gale
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway.

Authors:  M Kawada; S Yamagoe; Y Murakami; K Suzuki; S Mizuno; Y Uehara
Journal:  Oncogene       Date:  1997-08-07       Impact factor: 9.867

8.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

9.  Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs.

Authors:  Michael Frese; Verena Schwärzle; Kerstin Barth; Nicole Krieger; Volker Lohmann; Sabine Mihm; Otto Haller; Ralf Bartenschlager
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

10.  The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling.

Authors:  Andrew Macdonald; Katherine Crowder; Andrew Street; Christopher McCormick; Kalle Saksela; Mark Harris
Journal:  J Biol Chem       Date:  2003-03-05       Impact factor: 5.157

View more
  11 in total

1.  Coexistence of hepatitis B virus quasispecies enhances viral replication and the ability to induce host antibody and cellular immune responses.

Authors:  Liang Cao; Chunchen Wu; Hui Shi; Zuojiong Gong; Ejuan Zhang; Hui Wang; Kaitao Zhao; Shuhui Liu; Songxia Li; Xiuzhu Gao; Yun Wang; Rongjuan Pei; Mengji Lu; Xinwen Chen
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

2.  PCR-based in vitro synthesis of hepatitis C virus NS3 protease for rapid phenotypic resistance testing of protease inhibitors.

Authors:  Jinjuan Qiao; Junping Yu; Hang Yang; Hongping Wei
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

3.  Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells.

Authors:  Jin-Ching Lee; Chin-Kai Tseng; Kung-Chia Young; Hung-Yu Sun; Shainn-Wei Wang; Wei-Chun Chen; Chun-Kuang Lin; Yu-Hsuan Wu
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

4.  Betulinic acid exerts anti-hepatitis C virus activity via the suppression of NF-κB- and MAPK-ERK1/2-mediated COX-2 expression.

Authors:  Chun-Kuang Lin; Chin-Kai Tseng; Kai-Hsun Chen; Shih-Hsiung Wu; Chih-Chuang Liaw; Jin-Ching Lee
Journal:  Br J Pharmacol       Date:  2015-08-03       Impact factor: 8.739

5.  Study of vaccinia and cowpox viruses' replication in Rac1-N17 dominant-negative cells.

Authors:  Ana Paula Carneiro Salgado; Jamária Adriana Pinheiro Soares-Martins; Luciana Garcia Andrade; Jonas Dutra Albarnaz; Paulo César Peregrino Ferreira; Erna Geessien Kroon; Cláudio Antônio Bonjardim
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-08       Impact factor: 2.743

6.  Inhibition of miR-148a-3p resists hepatocellular carcinoma progress of hepatitis C virus infection through suppressing c-Jun and MAPK pathway.

Authors:  Yibin Deng; Jianchu Wang; Meijin Huang; Guidan Xu; Wujun Wei; Houji Qin
Journal:  J Cell Mol Med       Date:  2018-12-18       Impact factor: 5.310

7.  Celastrol inhibits hepatitis C virus replication by upregulating heme oxygenase-1 via the JNK MAPK/Nrf2 pathway in human hepatoma cells.

Authors:  Chin-Kai Tseng; Sung-Po Hsu; Chun-Kuang Lin; Yu-Hsuan Wu; Jin-Ching Lee; Kung-Chia Young
Journal:  Antiviral Res       Date:  2017-09-19       Impact factor: 5.970

Review 8.  Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection.

Authors:  Mirjam B Zeisel; Emilie Crouchet; Thomas F Baumert; Catherine Schuster
Journal:  Viruses       Date:  2015-11-02       Impact factor: 5.048

9.  Substituted 3-benzylcoumarins as allosteric MEK1 inhibitors: design, synthesis and biological evaluation as antiviral agents.

Authors:  Chao Wang; Hao Zhang; Fengrong Xu; Yan Niu; Yun Wu; Xin Wang; Yihong Peng; Jing Sun; Lei Liang; Ping Xu
Journal:  Molecules       Date:  2013-05-21       Impact factor: 4.411

Review 10.  Role of MAPK/MNK1 signaling in virus replication.

Authors:  Ram Kumar; Nitin Khandelwal; Riyesh Thachamvally; Bhupendra Nath Tripathi; Sanjay Barua; Sudhir Kumar Kashyap; Sunil Maherchandani; Naveen Kumar
Journal:  Virus Res       Date:  2018-06-01       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.